AU2002212614A1 - 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents - Google Patents
3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agentsInfo
- Publication number
- AU2002212614A1 AU2002212614A1 AU2002212614A AU2002212614A AU2002212614A1 AU 2002212614 A1 AU2002212614 A1 AU 2002212614A1 AU 2002212614 A AU2002212614 A AU 2002212614A AU 2002212614 A AU2002212614 A AU 2002212614A AU 2002212614 A1 AU2002212614 A1 AU 2002212614A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- hydrogen
- acetamido
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
3-(Heteroaryl acetamido)-2-oxo-azetidine-l -sulfonic acids derivatives as antibacterial agents
The present invention relates to novel Syn isomers of racemates and optical isomers of 3-(heteroaryl acetamido)-2-oxo-azetidine-l -sulfonic acids and its use in treating the infections caused by gram-negative pathogenic bacteria.
Background of Invention
Bacteria are very adaptable microorganisms that possess the ability to adapt and to survive under adverse conditions. Doctors in hospitals and clinics around the world are losing the battle against an onslaught of new drug resistant bacterial infections including those caused by Staphylococci, Streptococci, Enterococci and Pseudomonas.
Bacterial resistance to the current antibiotics has been on a steep rise due to the alteration ofthe target, a change in the permeability pattern or by efflux of active ingredient and by deactivation ofthe antibiotic before reaching the active site.
The β-lactam antibiotics (penicillins, cephalosporins, monobactams and carbapenems) are the most widely used group of antibiotics for the treatment of many infectious diseases, because of proven clinical efficacy and their excellent safety profile. Bacterial resistance towards gram-positive pathogens against β-lactam antibiotics is mainly due to the alteration of penicillin binding proteins (PBP's), efflux of active ingredient and deactivation of active ingredient. Whereas bacterial resistance towards gram-negative pathogens against β-lactam antibiotics in addition to those of the gram- positive pathogen, also are due to changes in outer membrane permeability pattern.
To overcome the changes in outer membrane permeability, in recent years a number of β-lactam compounds (cephem and monobactam) containing an iron chelating catecholic and dihydroxypyridone groups have been reported (29τh ICAAC, Houston Texas, Septembers, 1989, abstract no. 355, 356; 30τh ICAAC, Atlanta, Georgia, October 22, 1990, abstract no. 458; Antimicrobial Agents and chemotherapy 1991, 35, 104-110). The potent activity of these compounds is due to their utilization of the TonB-dependent iron transport systems for transport across the bacterial outer membrane (Antimicrobial Agents and chemotherapy 1995, 39, 613-619).
Monobactams are a class of antibacterial agents and have been used to treat infections caused by gram-negative microorganisms. Currently Aztreonam and Carumonam are in clinical use. Quinoxaline directly attached to an oxime side chain of the
monobactam nucleus is under development (Curr. Opin. Anti-infect. Drugs 1999, 1(1), 96- 100; Antimicrobial Agents and Chemotherapy 1997, 41, 1010-1016). Further dihydroxypyridine through a methylene spacer attached to an oxime side chain in the anti orientiation is reported as β-lactamase inhibitor (USP-5888998 (1999)).
The present invention describes a class of compound in which a dihydroxypyridone group is directly or through a suitable spacer attached to an oxime side chain in a monobactam nucleus and its use to treat gram-negative infections, particularly those caused by Pseudomonas. Pseudomonas aeruginosa continues to be a very frequent opportunistic pathogen, capable of causing a wide variety of infections in the immunocompromised patient. These infections are often associated with significant morbidity and are difficult to treat.
Summary ofthe Invention
It is an objective ofthe present invention to provide novel Syn isomers of racemates and optical isomers of 3-(heteroaryl acetamido)-2-oxo-azetidine-l -sulfonic acids of formula I having antibacterial activity against gram-negative pathogenic bacteria, particularly Pseudomonas strains.
(I)
It is a further object of the invention to provide pharmaceutical compositions comprising the compound of formula I with a pharmaceutically acceptable carrier or diluent.
It is an additional object of the invention to provide a method for treatment of bacterial infections caused by gram-negative pathogenic bacteria including Pseudomonas.
Detailed Description ofthe Invention hi accordance with the present invention, there is provided novel Syn isomers of recemates and optical isomers of 3-(heteroaryl acetamido)-2-oxo-azetidine-l -sulfonic acids of formula I
(I) Wherein
M is a hydrogen or a pharmaceutically acceptable salt forming cation;
X is CH, N or C-halo;
R is Cι-C3 alkyl which is unsubstituted or substituted with at least one of (a) a halogen atom (b) 0R5 wherein R5 is hydrogen, CONH2 or 2,5-dihydroxy-4-oxo-l,4-dihydro- pyridin-2-yl-carbonyl and wherein a d alkyl may not be substituted with both a halogen
Ri and R2 independently are OH, COOH, CONH2, optionally substituted phenyl or -C3 alkyl; or
Ri and R2 together are -0-CH=CH-CH2-, -0-CH2-CH2-0-, -CH2-CH2-CH2-,
-CH2-CH2-CH2-CH2-, -CH=CH-CH=CH- or -CH=C(OH)-C(OH)=CH- which together with the carbon atoms to which they are bound form a 5 membered or six membered cyclic ring
R3 and 1^ independently are hydrogen, optionally substituted Cι-C3 alkyl, optionally substituted phenyl or C3-C6 cycloalkyl; R3 and R4 together are C3-C6 cycloalkyl.
As used herein, the term "C1-C3 alkyl" means a straight or branch chain alkyl having 1-3 carbon atom selected from methyl, ethyl, propyl and isopropyl.
As used herein, the term "C3-Cg cycloalkyl" means a saturated alicyclic moiety having 3-6 carbon atoms selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As used herein, the term "halogen atom" means fluorine, chlorine, or bromine.
As used herein, the term "substituted" as applied to a group means substituted with 1, 2 or 3 substituents selected from OH, NH2, dimethylamino, a halogen atom, OCH3, COOH, CONH2, N02 or CN.
As used herein, the term "racemate" means the mixture of diastereoisomers having zero optical rotation ofthe molecule of formula I.
As used herein, the term "optical isomers" means pure single R and S diastereoisomers at the asymetric carbon atoms present in the molecule of formula I.
As used herein the term "pharmaceutically acceptable salt forming cation" means alkali metals (e.g. Sodium, Potassium), alkaline earth metals (e.g. Calcium, Magnesium), organic bases (e.g. triethylamine, ethanolamine, n-methylmorpholine) or basic amino acids (e.g. lysine, arginine, ornithine or histidine). Moreover when M is hydrogen in formula I, it can form zwitterions (inner salt or internal salt) by interacting with a basic nitrogen atom present in the molecule of formula I.
In accordance with the preferred embodiment of the present invention, there is provided novel Syn isomers of racemates and optical isomers of 3-(heteroaryl acetamido)- 2-oxo-azetidine-l -sulfonic acids and of formula I
(I)
Wherein
M is a hydrogen or pharmaceutically acceptable salt forming cation;
X is CH;
R is CH3, CH2F or CH2OCONH2.
R, is OH
R2 is Hydrogen;
Ri and R2 together is -CH=C(OH)-C(OH)=CH- which forms six member cyclic ring
R3 and R4 independently is hydrogen;
R3 and R4 together is cyclopropyl;
As used herein, the term "racemate" means the mixture of diastereoisomers having zero optical rotation of the molecule of formula I.
As used herein, the term "optical isomers" means pure single R and S diastereoisomers at the asymetric carbon atoms present in the molecule of formula I.
As used herein the term "pharmaceutically acceptable salt forming cation" means alkali metals (e.g. Sodium, Potassium). Moreover when M is hydrogen in formula I, it can form zwitterion (inner salt or internal salt) by interacting with a basic nitrogen atom present in the molecule of formula I.
The compounds of this invention can be used to treat bacterial infections caused by gram-negative bacteria, including but not limited to Pseudomonas E. eloaecae, C. freundii, M. Morganii, K. paeumoniae, and E. Coli, alone or in combination with other drugs in mammals including humans. The compounds may be administered in pharmaceutical dosage forms including parenteral preparation such as injections, suppositories, aerosols and the like, and oral preparations such as tablets, coated tablets, powders, granules, capsules, liquids and the like. The above preparations are formulated in manners well known to the art.
For the formulation of solid preparations for oral administration, an excipient, and if desired, a binder, disintegrator, lubricant, coloring agent, corrigent, flavor etc. are added to the compound ofthe invention, and then tablets, coated tablets, granules, powders, capsules or the like are prepared in a conventional manner.
For the formulation of injections, a pH adjusting agent, buffer, stabilizer, isotonic agent, local anesthetic or the like is added to the active ingredient of the invention, and injections for subcutaneous, intramuscular or intravenous administration can be prepared in the conventional manner.
For the formulation of suppositories, a base, and if desired, surfactants are added to the active ingredient of the invention, and the suppositories are prepared in a conventional manner.
The excipients useful for solid preparations for oral administration are those generally used in the art, and the useful examples are excipients such as lactose, sucrose, sodium chloride, starches, calcium carbonate, kaolin, crystalline cellulose, methyl cellulose, glycerin, sodium alginate, gum arabic and the like, binders such as polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, ethyl cellulose, gum arabic, schellac, sucrose, water, ethanol, propanol, carboxymethyl cellulose, potassium phosphate and the like, lubricants such as magnesium stearate, talc and the like, and further include additives such as usual known coloring agents, disintegrators and the like. Examples of bases useful for the formulation of suppositories are oleaginous bases such as cacao butter, polyethylene glycol, lanolin, fatty acid triglycerides, witepsol (trademark, Dynamite Nobel Co. Ltd.) and the like. Liquid preparations may be in the form of aqueous or oleaginous suspension, solution, syrup, elixir and the like, which can be prepared by a conventional way using additives.
The amount of the compound I of the invention incorporated into the pharmaceutical composition of the invention varies with the dosage form, solubility and chemical properties of the compound, administration route, administration scheme and the like. Preferably the amount is about 1 to 25 w/w% in the case of oral preparations, and about 0.1 to 5 w/w% in the case of injections which are parenteral preparations.
The dosage of the compound I of the invention is suitably determined depending on the individual cases taking symptoms, age and sex of the subject and the like into consideration. Usually the dosage in the case of oral administration is about 50 to 1500 mg per day for an adult in 2 to 4 divided doses, and the dosage in the case of injection, for example, by intravenous administration is 2 ml (about 1 to 100 mg) which is administered once a day for adults wherein the injection may be diluted with physiological saline or glucose injection liquid if so desired, and slowly administered over at least 5 minutes. The dosage in case of suppositories is about 1 to 1000 mg which is administered once or twice a day at an interval of 6 to 12 hours wherein the suppositories are administered by insertion into the rectum
The compounds of the present invention having the formula I can be prepared by reacting 3-amino-azetidine-2-one sulfonic acid of formula (II) with heteroaryl carboxylic acid of formula III followed by deprotection ofthe protecting group.
Scheme 1
Certain derivatives of general formula IV were prepared by coupling of 3-amino- azetidine-2-one sulfonic acid (II) with a heteroaryl carboxylic acid (III) in presence of dicyclohexylcarbodiimide (DCC) or with an acid chloride of compound (III) in presence of base, or with an activated ester of compound (III) within the skill ofthe arts.
Alternatively, compounds of formula I can also be prepared as follows:
The preparation of compound II (R= CH3) was carried out by following the synthetic scheme 2 as described in J. Org. Chem. 1982, 47, 5160-5167.
Scheme 2
R= trans CH3, Threoninε derived R= cis CH3, allo-threonine derived
The preparation of compound II (R=CH2F, CH2OCONH2) was carried out by following the synthetic scheme 3 from common intermediate compound V as described in J. Antibiotics 1983, 36, 1201-1204 and J. Antibiotics 1985, 38, 346-357.
Scheme 3
CONH.
The common intermediate compound V was prepared by following the synthetic route as described in scheme 4. The distereoisimers of compound VI are separated by optical resolution methods (J. Antibiotics 1985, 38, 346).
Scheme 4
HCOCOOCH,
C6H5
* represents cis isomers at carbon 3 and 4 The preparation of compounds III was done by reacting 2-heteroaryl-2-oxo acetic acid (VII) with O-heteroaryl hydroxyl amine (VIII) at room temperature and afforded exclusively the syn-isomer. The preparation of compound VIII was done as described in Scheme 5 starting from heteroarylmethanol (J. Antibiotics 1990, 43, 189-198).
Scheme 5
DEAD= Diethylazodicarboxylate
In the above descriptions (scheme 1-5), the reactants are reacted together with a suitable solvent at elevated or low temperatures for sufficient time to allow the reaction to proceed to completion. The reaction conditions will depend upon the nature and reactivity of the reactants. Wherever a base is used in a reaction, they are selected from triethylamine, tributylamine, trioctylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine, l,5-diazabicyclo[4,3,0]non-5-ene, l,8-diazabicyclo[5,4,0]undec-7-ene, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate or cesium carbonate.
The deprotection of the protective group is carried out either by hydrogenation or by hydrolysis with appropriate acids such as hydrochloric acid, trifluoroacetic acid or acetic acid in solvent such as methanol, ethanol, propanol or ethyl acetate. The hydrogenation reaction is usually carried out in the presence of a metal catalyst, such as Pd, Pt, or Rh, under normal pressure to high pressure.
The solvents of choice for the reaction are selected based upon the reactants used and from such solvents as benzene, toluene, acetonitrile, tetrahydrofuran, ethanol, methanol, chloroform, ethyl acetate, methylene chloride, dimethyl formamide, dimethyl sulfoxide, hexamethyl phosphoric triamide, or the like. Solvent mixtures may also be utilized.
Reaction temperatures would generally range from between -70°C to 150°C. The preferred molar ratio of reactants is 1:1 to 1:5. The reaction time range from 0.5 to 72 hours, depending on the reactants.
The present invention is further illustrated by the following non-limiting examples.
Example 1 (3S)-trans-3-[(2-Amino)thiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l -sulfonic acid, sodium salt Step 1 : 1 ,5-Dibenzhydryloxy-2-(N-phthalimido)oxymethyl-4-pyridone
A solution of l,5-dibenzhydryloxy-2-hydroxymethyl-4-pyridone (20.0g, 0.041mol) and N-hydroxyphthalimide (6.64g, 0.048mol) in a mixture of THF (200ml) and dry DMF (200ml) was treated with triphenyl phosphene under nitrogen and cooled to 0°C. The reaction mixture was then added with diethyl azodicarboxylate dropwise over 10 min., stirred at 0°C for lh then diluted with ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over sodium sulfate, filtered and evaporated in vacuo. The crude product obtained was purified by silica gel column chromatography using a gradient mixture of EA: Hexane (1:2 to 1:0) to give the pure title compound. Yield: 19.0g, 73%
'HNMR (DMSO-de): δ 4.78(s, 2H), 6.24(s, 1H), 6.29(s, 1H), 6.46(s, 1H), 7.18-7.38(m, 20H), 7.62(s, 1H), 7.85(s, 4H).
Step 2: 2-(2-Tritylamino)-thiazol-4-yl)-(Z)-2-[l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy]-imino acetic acid.
A solution of l,5-dibenzhydryloxy-2-(N-phthalimido)oxymethyl-4-pyridone (lOg, 15.8mmol) in ethanol (98%, 100ml) was treated with hydrazine (0.76ml). The mixture was heated to reflux for lh. and cooled to RT. The suspension thus obtained was filtered and the filtrate was evaporated to dryness and was treated with chloroform. The solid thus separated was filtered off, the mother liquors were concentrated and the residue obtained was dissolved in ethanol (98%) then treated with a solution of 2-oxo-2-[(N- tritylamino)thiazol-5-yl]acetic acid (6.38g ) in chloroform. The reaction mixture was stirred at room temperature for 18h and evaporated in vacuo. The residue obtained was dissolved in ethyl acetate and diluted with hexanes. The solid separated was filtered and dried to give 2-(2-tritylamino)thiazol-4-yl)-(Z)-2-[l,5-dibenzhydryloxy-4-pyridon-2-yl methoxyjimino acetic acid. Yield: 11.2g, 79%
1HNMR (DMSO-d6): δ 4.62(s, 2H), 6.03(s, IH), 6.28(s, IH), 6.40(s, IH), 6.66(s, IH), 7.18-7.35(m, 35H), 7.48(s, IH), 8.64(s, IH).
Step 3: (3S)-trans-3-[2-(2-Tritylamino)thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4- pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l-sulfonic acid.
A mixture of (3S)-trans-3-amino-4-methyl-2-oxoazctidine-l-sulfonic acid [7.30g, 40.52mmol, J. Org. Chem., 47, 5160, (1982)], 2-(2-tritylamino)thiazol-4-yl)-(Z)-2-[l,5- dibenzhydryloxy-4-pyridon-2-yl methoxyjimino acetic acid (from step 36.50g, 40.51mmol), DCC (9.15g, 44.34 mmol) and 1 -hydroxybenzotriazole (5.47g, 40.5mmol) in dry DMF (400ml) was stirred at room temperature for 30 min. and to this mixture NaHC03 (3.40g, 40.52mmol) was added. The mixture was stirred under nitrogen at room temperature over night and filtered. The mother liquor was evaporated in vacuo to remove DMF and the residue obtained was dissolved in ethyl acetate and distilled water and adjusted to pH ~3. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo.
The product thus obtained was purified over HP-20 column chromatography using a gradient mixture of water: acetonitrile (1:0 to 1:9) to give the title compound. Silica gel column chromatography using a gradient mixture of ethyl acetate: methanol (1:0 to 9:1) gave the title compound Yield: 37.00g, 85.9%
'HNMR (DMSO-d6): δ 1.29(d, 3H, J=6.0Hz), 3.54-3.61(m, IH), 4.30-4.35(m, IH), 4.70(s, 2H), 5.98(s, IH), 6.29(s, 2H), 6.71(s, IH), 7.25-7.35(m, 35H), 7.5 l(s, IH), 8.83(s, IH), 9.39(d, IH, J=7.7Hz).
Step 4: (3S)-trans-3-[(2-Amino)thiazol-4-yl)-(Z)-2- {(1 ,5-dihydroxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l-sulfonic acid.
A suspension of (3S)-trans-3-[-2-(2-tritylamino)thiazol-4-yl)-(Z)2-{(l,5-
dibenzhydryloxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l- sulfonic acid (5.00g, 4.703mmol) in dry anisole (14ml) at -10°C, under nitrogen was treated with trifluoroacetic acid (25ml) and stirred at 0°C for 2 hrs. The solvents were evaporated under reduced pressure and the residue was triturated with a mixture of ether- hexane and ethyl acetate (1:1: 1). The solid thus obtained was filtered, washed with a mixture of ether-hexane and ethyl acetate (1:1:1) to give a solid. The above solid was
further purified by HP-20 column chromatography using a gradient mixture of distilled water and acetonitrile (1:0 to 9:1) and the appropriate fractions were lyophilized to give the title compound.
Yield: 2.7g, 92%; mp: 200°C decomp.
'FINMR (DMSO-d6): δ 1.41(d, 3H, J=6.2Hz), 3.70-3.80(m, IH), 4.46(dd, IH, J=2.4Hz and
5.2Hz), 5.30(s, 2H), 6.85(s, IH), 7.05(s, IH), 7.35(br, s, 2H): 8.17(s, IH), 9.50(d, IH,
J=7.7Hz).
Step 5: (3S)-trans-3-[(2-Amino)thiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l-sulfonic acid, sodium salt.
A suspension of (3S)-trans-3-[(Z)-(2-amino)thiazol-4-yl)-2-{(l,5-dihydroxy-4- pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l -sulfonic acid (1.30g, 2.66mmol) in distilled water (15ml) was cooled to ~5-6°C and NaHC03 (s, 0.223g, 2.654mmol) was added in portions with stirring. The clear solution thus obtained within 10 min. was filtered and lyophilized to give (3S)-trans-3-[{(2-amino)thiazol-4-yl)-(Z)-2-{(l,5- dihydroxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-methyl-2-oxoazetidine-l-sulfonic acid, sodium salt. Yield: 1.32g, 97.13%.
1HNMR (DMSO-dβ): δ 1.42(d, 3H, J=6.1Hz), 3.70-3.80(m, IH), 4.48-4.53(m, IH), 5.13(s, 2H), 6.64(s, IH), 6.79(s, IH), 7.24(br, s, 2H), 7.68(s, IH), 9.52(d, IH, J=7.0Hz).
Example 2 3-[2-(2-Aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy)imino}- acetamido]-4-carbamoyloxymethyl-2-azetidinone-l -sulfonic acid, sodium salt
Step 1 : 3-[2-(2-Tritylamino)-thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-carbamoyloxymethyl-2-azetidinone
A solution of 2-(2-tritylamino)-thiazol-4-yl)-(Z)-2-[l,5-dibenzhydryloxy-4-pyridon- 2-yl methoxyjimino acetic acid (0.34g, 0.377mmol) in dry DMF (20ml) was treated with DCC (0.078g, 0.377mmol) and 1 -hydroxybenzotriazole (0.050g, 0.0377mmol). The mixture was stirred under nitrogen at room temperature for 30 min. and to this mixture NaHC03 (0.032g, 0.377mmole) and 3-amino-4-carbamoyloxymethyl-2-azetidinone (0.06g, 0.377mmol) in DMF (5ml) was added. The reaction mixture was stirred at room temperature for 18hrs, and DMF was removed in vacuo. The product thus obtained was purified by silica gel column chromatography by a gradient mixture of ethyl acetate and methanol (10:1 to 9.5:0.5) to give the title compound. Yield: 0.2g, 97.13%
1HNMR (DMSO-d6): δ 3.80-3.92(m, 2H), 3.97-4.05(m, IH), 4.70(s, 2H), 5.17-5.25(m, IH), 6.00(s, IH), 6.3 l(s, IH), 6.53(br, s, 2H), 6.74(s, IH), 7.24-7.38(m, 35H), 7.58(s, IH), 8.50(s, IH), 8.80(s, IH), 9.29(d, IH, J=9.0Hz).
Step 2: 3-[{2-(2-Tritylamino)thiazol-4-yl)}-(Z)-2-{(l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy)imino } acetamido]-4-carbamoyloxymethyl-2-azetidinone- 1 -sulfonic acid
A solution of 3-[{2-(2-tritylamino)thiazol-4-yl)}-(Z)-2-{(l,5-dibenzhydryloxy-4- pyridon-2-yl methoxyjimino } acetamido] -4-carbamoyloxymethyl-2-azetidinone (0.25 g, 0.244mmol) in pyridine (2ml) was treated with sulfur trioxide-pyridine complex (0.153g, 0.96mmol) and the mixture was heated at 70 C for 45 min. The reaction mixture was cooled to RT, treated with diethyl ether and the solid was filtered, washed with distilled water followed by ether and dried to give ciss-3-[{2-(2-tritylamino)thiazol-4-yl)}-(Z)-2- {(l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-carbamoyloxy methyl-2-azetidinone- 1 -sulfonic acid. Yield: 0.23g, 85%
Step 3: 3-[2-(2-Tritylamino)-thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy)imino } acetamido]-4-carbamoyloxymethyl-2-azetidinone- 1 -sulfonic acid, sodium salt.
A suspension of 3-[2-(2-tritylamino)-thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4- pyridon-2-yl methoxy)imino}acetamido]-4-carbamoyloxymethyl-2-azetidinone-l-sulfonic acid (0.390g, 0.353mmol) in distilled water (10ml) was treated with NaHC03 (s, 0.050g, 0.595mmol) and stirred at RT for 30 min. and the clear solution was lyophilized. The solid obtained was purified by HP-20 column chromatography using a gradient mixture of dd. Water and acetonitrile (1:0 to 3:7), and the appropriate fractions were lyophilized to give the to give 3-[2-(2-tritylamino)-thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-carbamoyloxymethyl-2-azetidinone-l-sulfonic acid, sodium salt.
Yield: 0.2 lg, 52%
Step 4: 3-[2-(2-Aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy)imino } acetamido]-4-carbamoyloxymethyl-2-azetidinone- 1 -sulfonic acid.
A suspension of 3-[2-(2-tritylamino)thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4- pyridon-2-yl methoxy)imino} acetamido]-4-carbamoyloxymethyl-2-azetidinone- 1 -sulfonic acid, sodium salt (0.8g, 0.874mmol) in anisole (5ml) under nitrogen atmosphere was cooled to ~0 C and treated with trifluoroacetic acid (25ml) and the mixture was stirred at less than 10 C for 2hrs and treated with ether. The solid separated was filtered, washed with acetone and dissolved in a mixture of acetonitrile/dd. H20 and freeze dried to give the title compound.
Yield: 0.34g, 89%; mp: 190° decomp.
1HNMR (DMSO-d6): δ 3.90-4.30(m, 3H), 5.22-5.40(m, 5H), 6.50(br, s, 2H), 6.82(s, IH), 6.95(s, IH), 7.33(br, s, 2H), 8.00(s, IH), 9.45(d, IH, J=7.5Hz). Step 5: 3-[2-(2-Aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy)imino } acetamido] -4-carbamoyloxymethyl-2-azetidinone- 1 -sulfonic acid, sodium salt
NaHC03 (s, 6mg,0.073mmol) was added to a suspension of 3-[2-(2-Aminothiazol- 4-yl)-(Z)-2- {( 1 ,5 -dihydroxy-4-pyridon-2-yl-methoxy)imino} -acetamido]-4- carbamoyloxymethyl-2-azetidinone-l -sulfonic acid (40mg, 0.073mmol) in distilled water. After stirring for 5 min. the mixture was freeze dried to give the title compound as a solid. Yield: 30mg, 71%
1HNMR (DMSO-de): δ 4.03-4.15(m, 2H), 4.20-4.33(m, IH), 5.12(s, 2H), 5.26-5.37(m, IH), 6.54(br, s, 2H), 6.70(s, IH), 6.77(s, IH), 7.24(br, s, 2H), 7.72(s, IH), 9.38(d, IH, J=7.5Hz).
Example 3 3-[2-(2-Aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl-methoxy)imino}- acetamido]-4-fluoromethyl-2-azetidinone-l -sulfonic acid, sodium salt Step 1 : 3-[2-(2-Tritylamino)-thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4-pyridon-2-yl methoxy)imino}acetamido]-4-fluoromethyl-2-azetidinone-l-sulfonic acid.
A solution of 3-(N-benzyloxycarbonyl)amino-4-fluoromethyl-2-azetidinone-l- sulfonic acid, tetrabutyl ammonium salt (0.5g, 0.89mmol) in DMF (20ml) was treated with Pd-C (0.3g) and the suspension was hydrogenated at 50 psi over 5 hrs. The suspension was filtered through celite and to the filtrate was added DCC (0.18g, 0.89mmol), 1-HBT (0.12g, 0.89mmol) followed by 2-{(2-tritylamino)-thiazol-4-yl}-(Z)-2-[l,5-dibenzhydryloxy-4- pyridon-2-yl methoxyjimino acetic acid (0.4g, 0.89mmol). The reaction mixture was stirred at RT for 18 hrs and evaporated in vacuo. The residue was dissolved in acetone treated with potassium nonafluoroborate (0.6g) in acetone and stirred for a further 18 hrs. The solvents were evaporated and the residue was treated with a mixture of Ethyl acetate- Ether-Hexane (1:1:1). The solid separated was filtered and purified by silica gel column
chromatography using a gradient mixture of Ethyl acetate and methanol (10: 1 to 9:1) to give the title compound.
Yield: 0.22g, 42.8%
'HNMR (DMSO-d6): δ 4.00-4.20(m, 2H), 4.40-4.50(m, IH), 4.67(s, 2H), 5.16-5.24(m,
IH), 6.00(s, IH), 6.32(s, IH), 6.37(s, IH), 6.67(s, IH), 7.27-7.43(m, 35H), 7.63(s, IH),
8.85(s, IH), 9.46(d, IH, J=9.0Hz).
Step 2: 3-[2-(2-Aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy) imino}-acetamido]-4-fluoromethyl-2-azetidinone-l -sulfonic acid, sodium salt.
A suspension of 3-[2-(2-tritylamino)thiazol-4-yl)-(Z)-2-{(l,5-dibenzhydryloxy-4- pyridon-2-yl methoxy)imino} acetamido]-4-fluoromethyl-2-azetidinone-l-sulfonic acid (0.5g, 0.46mmol) in anisole (2ml), under nitrogen at -10°C was treated with trifluoroacetic acid (20ml) and stirred at 5-10°C for 2hrs. The reaction mixture was evaporated in vacuo and the residue was triturated with a mixture of ether: ethyl acetate and hexanes (1:1: 1). The solid separated was filtered, dissolved in acetonitrile, water mixture and freeze dried. The crude product obtained was further purified by HP-20 column chromatography using a gradient mixture of dd.H20 and acetonitrile (1: 0 to 9.4 : 0.6) to give 3-[2-(2-aminothiazol- 4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy)imino}-acetamido]-4-fluoromethyl-2- azetidinone-1 -sulfonic acid. Yield: 80mg, 34%; M.pt: 200°C decomp.
1HNMR (DMSO-d6): δ 3.83-4.35(m, 2H), 4.47-4.63(m, IH), 4.68-4.85(m, IH), 5.28(s, 2H), 6.29(s, IH), 7.03(s, IH), 7.30(br, s, 3H), 8.12(s, IH), 9.45(d, IH, J=8.1Hz). Step 3: 3-[2-(2-Aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl methoxy) imino}-acetamido]-4-fluoromethyl-2-azetidinone-l-sulfonic acid, sodium salt
NaHC03 (s, 13mg, 0.155mmol) was added to a suspension of 3-[2-(2-Aminothiazol-4-yl)- (Z)-2-{(l,5-dihydroxy-4-pyridon-2-yl- methoxy) imino}-acetamido]-4-fluoromethyl-2- azetidinone-1 -sulfonic acid (80mg, 0.158mmol) in distilled water. The mixture was stirred for 5 min. and freeze dried to give 3-[2-(2-aminothiazol-4-yl)-(Z)-2-{(l,5-dihydroxy-4- pyridon-2-yl methoxy)imino}- acetamido]-4-fluoromethyl-2-azetidinone-l -sulfonic acid, sodium salt. Yield: 75mg, 89%
'HNMR (DMSO-de): δ 3.83-4.30(m, 2H), 4.47-4.64(m, IH), 4.73-4.84(m, IH), 5.13(s, 2H), 5.30(s, IH), 6.55(s, IH), 6.74(s, IH), 7.27(br, s, 2H), 7.57(s, IH), 9.57(br, s, IH).
Test for Antibacterial Activity
The compounds of the present invention were tested for minimum inhibitory concentration (MIC) against the bacteria listed in Table- 1 according to the standard microbroth dilution method as described in NCCLS document. The minimum inhibitory concentration is expressed in μg/ml.
Table 1: Antibacterial activity of the compounds of formula I
Claims (19)
1. A compound selected from the group consisting of a Syn isomer of a racemate and an optical isomer of 3 -(heteroaryl acetamido)-2-oxo-axetidine-l -sulfonic acid and of formula I
(I) Wherein
M is a hydrogen or pharmaceutically acceptable salt forming cation; X is CH, N or C-halogen;
R is Cι-C3 alkyl which is unsubstituted or substituted with at least one of (a) a halogen atom (b) OR5 wherein R5 is hydrogen, CONH2 or 2,5-dihydroxy-4-oxo- l,4-dihydro-pyridin-2-yl-carbonyl, wherein cannot be substituted with both a halogen atom and OR5.
Ri and R2 independently are OH, COOH, CONH2, NH2, dimethylamino, OCH3, N02, CN optionally substituted phenyl or Cι-C3 alkyl; or Ri and R2 together are -0-CH=CH-CH2-, -0-CH2-CH2-0-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH=CH-CH=CH- or -CH=C(OH)-C(OH)=CH- which together with the carbon atoms to which they are bound form a 5 membered or six membered cyclic ring; and
R3 and R4 independently are hydrogen, optionally substituted C1-C3 alkyl, optionally substituted phenyl or C3-C6 cycloalkyl; or R3 and R) together are C3-C6 cycloalkyl.
2. A compound of formula I as set forth in claim 1, wherein at least one of R, Ri, R2j R3) and R4 are selected from the group consisting of methyl, ethyl, propyl and isopropyl.
3. A compound of formula I as set forth in claim 1, wherein R3 and R4 are independently a saturated alicyclic moiety having 3-6 carbon atoms selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
4. A compound of formula I as set forth in claim 1, wherein the halogen atom is selected from the group consisting of fluorine, chlorine, and bromine.
5. A compound of formula I as set forth in claim 1, wherein the substitutents are 1, 2 or 3 substituents selected from OH, NH2, dimethylamino, halogen atom, OCH3, COOH, CONH2, N02 or CN.
6. A compound of formula I as set fortli in claim 1, wherein the pharmaceutically acceptable salt forming cation is selected from the group consisting of alkali metals, alkaline earth metals, organic bases or basic amino acids.
7. A method of producing a zwitterion of the compound of claim 1 wherein M is hydrogen, and wherein said compound is interacted with a basic nitrogen atom present in the molecule of formula I.
8. A compound of formula I
(I) Wherein
M is a hydrogen or pharmaceutically acceptable salt forming cation;
X is CH;
R is CH3, CH2F or CH2OCONH2.
Ri is OH R2 is Hydrogen; or
Ri and R2 together are -CH=C(OH)-C(OH)=CH- which, together with the catons to which Ri and R2 are bound, forms a six member cyclic ring; and
R3 and R independently are hydrogen; or
R3 and R4 together are cyclopropyl.
9. A pharmaceutical composition suitable for the treatment of bacterial infections in mammals comprising the compound described in claim 1 or claim 8 or pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.
10. The use of compounds described in claim 1 or claim 8 for treatment of bacterial infections in warm-blooded animals.
11. A method of treating a bacterial infection in a subject in need of such treatment comprising administering to said subject in need of such treatment a therapeutically effective amount ofthe compound of claim 1 or claim 8.
12. An oral preparation comprising about 1 to 25 w/w% of the compound of claim 1 or claim 8.
13. A parenteral preparation comprising about 0.1 to 5 w/w% ofthe compound of claim 1 or claim 8.
14. The method of claim 11, wherein the therapeutically effective amount of the compound of claim 1 or claim 8 comprises an oral dosage of about 50 to 1500 mg/day ofthe compound of claim 1 or claim 8 for an adult in 2-4 divided doses.
15. the method of claim 11, wherein the therapeutically effective amount of compound of claim 1 or claim 8 comprises an injection of about l-100mg of the compound of claim 1 or claim 8.
16. The method of claim 17, wherein the therapeutically effective amount of the compound of claim 1 or claim 8 is diluted with physiological saline of glucose injection liquid.
17. The method of claim 11, wherein the therapeutically effective amount of the compound of claim 1 or claim 8 comprises a suppository containing about 1-1000 mg ofthe compound of claim 1 or 8.
18. A method of producing a compound of formula I comprising (a) reacting a 3- amino-azetidine-2-one sulfonic acid of formula (II) with a heteroaryl carboxylic acid of formula (III) and (b) deprotecting the protecting group.
19. A compound of formula I as set forth in claim 1, wherein the racemate is the mixture of diastereoisomers having zero optical rotation ofthe molecule.
0. A compound of formula I as set forth in claim 1, wherein the optical isomer is a pure single R and S diasteroisomer at an asymmetric carbon atom present in the molecule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23261700P | 2000-09-14 | 2000-09-14 | |
| US60/232,617 | 2000-09-14 | ||
| PCT/IB2001/002115 WO2002022613A1 (en) | 2000-09-14 | 2001-09-14 | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002212614A1 true AU2002212614A1 (en) | 2002-06-13 |
| AU2002212614B2 AU2002212614B2 (en) | 2006-12-07 |
Family
ID=22873854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002212614A Ceased AU2002212614B2 (en) | 2000-09-14 | 2001-09-14 | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| AU1261402A Pending AU1261402A (en) | 2000-09-14 | 2001-09-14 | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU1261402A Pending AU1261402A (en) | 2000-09-14 | 2001-09-14 | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6916803B2 (en) |
| EP (1) | EP1322648B1 (en) |
| JP (1) | JP2004509122A (en) |
| KR (1) | KR100854810B1 (en) |
| CN (1) | CN1189469C (en) |
| AT (1) | ATE298750T1 (en) |
| AU (2) | AU2002212614B2 (en) |
| BR (1) | BR0113861A (en) |
| CA (1) | CA2422375C (en) |
| CZ (1) | CZ304586B6 (en) |
| DE (1) | DE60111757T2 (en) |
| DK (1) | DK1322648T3 (en) |
| ES (1) | ES2244666T3 (en) |
| HK (1) | HK1054377A1 (en) |
| HU (1) | HUP0301025A3 (en) |
| IL (2) | IL154593A0 (en) |
| NO (1) | NO324946B1 (en) |
| NZ (1) | NZ524292A (en) |
| PL (1) | PL218196B1 (en) |
| PT (1) | PT1322648E (en) |
| SK (1) | SK2462003A3 (en) |
| WO (1) | WO2002022613A1 (en) |
| ZA (1) | ZA200302085B (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012233003B2 (en) * | 2005-12-07 | 2014-12-18 | Basilea Pharmaceutica Ag | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
| PT2308874E (en) | 2005-12-07 | 2013-04-26 | Basilea Pharmaceutica Ag | Bridged monobactams useful as beta-lactamase inhibitors |
| RU2488394C2 (en) * | 2007-03-23 | 2013-07-27 | Базилеа Фармацойтика Аг | Combined therapeutic agents for treating bacterial infections |
| WO2009114921A1 (en) * | 2008-03-17 | 2009-09-24 | Dmitrienko Gary I | INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES |
| JP6266978B2 (en) | 2010-08-10 | 2018-01-24 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | Cyclic boronate derivatives and therapeutic uses thereof |
| US9012491B2 (en) | 2011-08-31 | 2015-04-21 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| UY34585A (en) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | B-LACTAMIC COMPOUNDS REPLACED WITH AMIDINE, ITS PREPARATION AND USE |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN102757405B (en) * | 2012-07-25 | 2014-04-16 | 山东理工大学 | Vanilline derivative containing thiadiazole, preparation method and purpose thereof |
| US9642869B2 (en) | 2013-01-04 | 2017-05-09 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2014107536A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| LT3140310T (en) | 2014-05-05 | 2019-11-25 | Rempex Pharmaceuticals Inc | Synthesis of boronate salts and uses thereof |
| WO2015171398A1 (en) | 2014-05-05 | 2015-11-12 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| BR112016026291A2 (en) | 2014-05-19 | 2017-08-15 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF |
| KR20170024087A (en) | 2014-07-01 | 2017-03-06 | 렘펙스 파머수티클스 인코퍼레이티드 | Boronic acid derivatives and therapeutic uses thereof |
| US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US10364257B2 (en) | 2014-12-19 | 2019-07-30 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA3026582A1 (en) | 2016-06-30 | 2018-01-04 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN107641119B (en) | 2016-07-21 | 2019-11-08 | 中国科学院上海药物研究所 | Monocycle beta-lactam-siderophore conjugates and its preparation method and application |
| US20200093814A1 (en) | 2016-12-21 | 2020-03-26 | Aicuris Gmbh & Co. Kg | Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains |
| MX2020003495A (en) | 2017-10-11 | 2020-09-18 | Qpex Biopharma Inc | Boronic acid derivatives and synthesis thereof. |
| CN111511737B (en) | 2018-01-29 | 2022-10-18 | 南京明德新药研发有限公司 | Monocyclic beta-lactam compounds for the treatment of bacterial infections |
| WO2020125670A1 (en) | 2018-12-18 | 2020-06-25 | 南京明德新药研发有限公司 | APPLICATION OF MONOCYCLIC β-LACTAM COMPOUND IN PHARMACY |
| SI25892A (en) * | 2019-09-05 | 2021-03-31 | Gorenje Gospodinjski Aparati, D.O.O. | Washing machine that is charged from the front with an electric lightbody |
| US11040987B2 (en) | 2019-09-11 | 2021-06-22 | Tennor Therapeutics Limited | Penam derivatives for treating bacterial infections |
| JP7446424B2 (en) | 2019-11-22 | 2024-03-08 | スージョウ アーイェ ファーマシューティカル カンパニー リミテッド | Sulfonylurea ring-substituted monocyclic β-lactam antibiotics |
| WO2021121387A1 (en) | 2019-12-19 | 2021-06-24 | 南京明德新药研发有限公司 | Application of compound in drug preparation |
| CN113754651B (en) * | 2020-06-02 | 2023-04-18 | 中国医学科学院医药生物技术研究所 | Beta-lactam compound, application and preparation method thereof |
| CA3229556A1 (en) * | 2021-08-20 | 2023-02-23 | Marvin Miller | Conjugates of monocyclic beta-lactams and siderophore mimetics |
| CN115304594B (en) | 2022-10-12 | 2023-02-14 | 苏州二叶制药有限公司 | Salt form of sulfonylurea ring-substituted compound and crystal form thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632985A (en) | 1985-06-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | 3-acylamino-2-oxo-1-azetidinesulfonic acids |
| GB8810396D0 (en) | 1988-05-03 | 1988-06-08 | Glaxo Group Ltd | Chemical process |
| US5112968A (en) * | 1989-07-28 | 1992-05-12 | E. R. Squibb & Sons, Inc. | Monobactam hydrazide derivatives |
| US5250691A (en) * | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
| US5888998A (en) * | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
| US5994340A (en) * | 1997-08-29 | 1999-11-30 | Synphar Laboratories, Inc. | Azetidinone derivatives as β-lactamase inhibitors |
-
2001
- 2001-09-14 CN CNB018157319A patent/CN1189469C/en not_active Expired - Fee Related
- 2001-09-14 PL PL360537A patent/PL218196B1/en unknown
- 2001-09-14 JP JP2002526866A patent/JP2004509122A/en active Pending
- 2001-09-14 CZ CZ2003-606A patent/CZ304586B6/en not_active IP Right Cessation
- 2001-09-14 AU AU2002212614A patent/AU2002212614B2/en not_active Ceased
- 2001-09-14 CA CA2422375A patent/CA2422375C/en not_active Expired - Fee Related
- 2001-09-14 IL IL15459301A patent/IL154593A0/en active IP Right Grant
- 2001-09-14 DK DK01980829T patent/DK1322648T3/en active
- 2001-09-14 ZA ZA200302085A patent/ZA200302085B/en unknown
- 2001-09-14 AU AU1261402A patent/AU1261402A/en active Pending
- 2001-09-14 EP EP01980829A patent/EP1322648B1/en not_active Expired - Lifetime
- 2001-09-14 WO PCT/IB2001/002115 patent/WO2002022613A1/en active IP Right Grant
- 2001-09-14 BR BR0113861-8A patent/BR0113861A/en active Search and Examination
- 2001-09-14 SK SK246-2003A patent/SK2462003A3/en unknown
- 2001-09-14 AT AT01980829T patent/ATE298750T1/en active
- 2001-09-14 KR KR1020037003718A patent/KR100854810B1/en not_active IP Right Cessation
- 2001-09-14 PT PT01980829T patent/PT1322648E/en unknown
- 2001-09-14 US US10/363,222 patent/US6916803B2/en not_active Expired - Fee Related
- 2001-09-14 NZ NZ524292A patent/NZ524292A/en unknown
- 2001-09-14 HU HU0301025A patent/HUP0301025A3/en unknown
- 2001-09-14 ES ES01980829T patent/ES2244666T3/en not_active Expired - Lifetime
- 2001-09-14 DE DE60111757T patent/DE60111757T2/en not_active Expired - Lifetime
-
2003
- 2003-02-24 IL IL154593A patent/IL154593A/en not_active IP Right Cessation
- 2003-03-13 NO NO20031162A patent/NO324946B1/en not_active IP Right Cessation
- 2003-09-03 HK HK03106287A patent/HK1054377A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1322648B1 (en) | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | |
| AU2002212614A1 (en) | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | |
| EP0893446B1 (en) | Cephem compounds and drugs containing the compounds | |
| JP2021519320A (en) | New albicidin derivatives, their use and synthesis | |
| JP3164390B2 (en) | Antibacterial agent | |
| EP0266896B1 (en) | 7-( (meta-substituted) phenylglycine) 1-carba-1-dethiacephalosporins | |
| OGINO et al. | NEW AMINOTHIAZOLYLGLYCYLCEPHALOSPORINS WITH A 1, 5-DIHYDROXY-4-PYRIDONE-2-CARBONYL GROUP I. SYNTHESIS AND BIOLOGICAL ACTIVITY OF CEPHALOSPORIN DERIVATIVES LEADING TO MT0703 | |
| EP0269087A2 (en) | Cephalosporin derivatives, processes for the preparation of the same, intermediates for use in the synthesis of the same, pharmaceutical compositions comprisingthe same, and the use of the same for the manufacture of a medicament having valuable therapeutic and preventative properties | |
| KR900003563B1 (en) | Process for preparing cephalosporin derivatives | |
| KR100274736B1 (en) | Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin | |
| JPS59199693A (en) | Indolylglycylcephalosporin derivative | |
| EP3634974B1 (en) | Tunicamycin analogues | |
| KR20220061163A (en) | Siderophore cephalosporin conjugates and uses thereof | |
| CN101220056A (en) | Use of fluoroquinolone containing phosphoric acid ester group | |
| JP2006052138A (en) | Proline derivative | |
| JP2006052140A (en) | Proline derivative | |
| JP2006052139A (en) | Proline derivative | |
| JPS638956B2 (en) | ||
| HU180307B (en) | Process for producing new 7-beta-square bracket bracket-2,3-dioxo-1-piperazine-carboxamido-aracket closed-hydroxy-amido-square bracket closed-7-alpha-metoxy -ceph-3-eme-4-carboxylic acid derivatives |